Do antibodies to β2-glycoprotein 1 contribute to the better                 characterization of the antiphospholipid syndrome?

Detková, Drahomíra; Gil‐Aguado, Antonio; Lavilla, P; Cuesta, M V; Fontaán, G; Pascual‐Salcedo, Dora

doi:10.1177/096120339900800604

Cited by 39 publications

(26 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent investigations addressing this issue [72,89,[102][103][104][105][106][107][108][109] found that multiple positivity in tests exploring the presence of aPL is more frequently associated with thromboembolic events and pregnancy morbidity than single-test positivity. Much of the controversy stems from the poor standardization of the laboratory detection procedures.…”

Section: Discussionmentioning

confidence: 99%

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

Tripodi

Groot

Pengo³

2011

Journal of Internal Medicine

View full text Add to dashboard Cite

Abstract. Tripodi A, de Groot PG, Pengo V (IRCCS Cà Granda Ospedale Maggiore Policlinico Foundation and Università degli Studi di Milano, Milan, Italy; Utrecht University Medical Center, Utrecht, the Netherlands; Thrombosis Center, University Hospital, Padua, Italy). Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment (Review). J Intern Med 2011; 270: 110-122.The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and ⁄ or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and ⁄ or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12 weeks apart) for lupus anticoagulants and ⁄ or antibodies targeted against cardiolipin or b 2 -glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

Tripodi

Groot

Pengo³

2011

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…The OD units for each result were calculated on the basis of the standard curve. Samples with <10 GPL units, [10][11][12][13][14][15][16][17][18][19][20] Of the total patients, 19 were with low, moderate or high aCL-aPI antibody levels (Table I a aCL+; of the patients CA19.9 positive 37.5% was aCL+ and 62.5% aPI+; of the patients CEA-CA19.9 30% was aCL+ and 30% aPI+; of the patients CA125 positive 9% was aPI+; of the patients CEA-CA125 positive 100% was aPI+; of the patients CEA-CA15.3 25% was aCL+ and 25 aPI+ (Fig. 3).…”

Section: Igm- Igg-acl and Igm- Igg -Api Evaluationmentioning

confidence: 99%

“…Nevertheless, testing only for aCL antibodies does not always permit detection of all aPLs, especially when only IgG are evaluated. In fact, the majority of APS patients had aCL or lupus anticoagulant (LAC) antibodies, but some of them had only monospecific aPL antibodies, reacting against phosphatidylinositol and phosphatidylserine, which the conventional aCL assay fails to detect (17)(18). In the selected population of patients affected by deep venous thrombosis (DVT), moderate or high levels of antiphosphatidylinositol (aPI) and/or antiphosphatidylserine (aPS) antibodies, but no aCL antibodies, were found in 8.1% patients.…”

mentioning

confidence: 99%

Antiphospholipid Antibodies in Patients with Cancer

Pugliese¹,

Bernardini²,

Pacifico³

et al. 2006

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Antiphospholipid antibodies are generally associated with Antiphospholipid Syndrome, which can occur as a primary disorder or may be secondary to connective tissue disease or tumour. The presence of antiphospholipid antibodies in patients with tumour disease is responsible for thrombotic complications. In a population of 53 tumor patients with positive carcinoembryonic antigen CEA, carbohydrate antigen CA19.9, CA125 and CA15.3 markers, IgM and IgG anticardiolipin and antiphosphatidylinositol were detected by solid-phase immunoassays. Our results show that moderate or high levels of antiphospholipid antibodies are present in a great number of patients with CEA and CA19.9 markers, suggesting a specific association with gastroenteric tumors. By testing for antiphosphatidylinositol antibodies, many patients not evidenced by the standard anticardiolipin assay were found to be antiphospholipid-positive. The analysis of antiphosphatidylinositol antibodies as a diagnostic tool in gastroenteric cancer to highlight patients with the risk of thromboembolic complications is discussed.

show abstract

“…monospecific aPL antibodies, reacting against PI and PS, which the conventional aCL assay fails to detect (8,9). The mechanism by which these antibodies are induced and the nature of the association of aPL with thrombosis is unknown.…”

mentioning

confidence: 99%

Antiphosphatidylinositol Antibody in Deep Venous Thrombosis Patients

Panarelli¹,

Mp²,

Albi³

2003

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Antiphospholipid antibodies are a heterogeneous group of immunoglobulins with specificity for a number of phospholipids, phospholipid-binding proteins and phospholipid-protein complexes. The association between antiphospholipid antibodies and a variety of pathologic disorders, such as arterial and venous thrombosis and recurrent pregnancy loss is recognized as Antiphospholipid Syndrome. The immunoassay currently used to detect antiphospholipid antibodies is the anticardiolipin test. Anticardiolipin antibodies are believed to be polyspecific antibodies that cross-react with all the anionic phospholipids. Therefore, testing only for anticardiolipin antibodies does not always permit detection of all antiphospholipid antibodies, specially when only IgG are evaluated.In a selected population of 74 idiopathic and secondary deep venous thrombosis patients, IgG anticardiolipin, antiphosphatidylinositol and antiphosphatid~lserineantibodies were detected by solidphase immunoassays. Our results show that by testing for each antiphospholipid family, many patients, not evidenced by the standard anticardiolipin assay, were found to be antiphospholipid-positive. The anticardiolipin positive patients have always low, moderate or high levels of antiphospholipid antibodies, suggesting that the antiphospholipid positivity is predictive of anticardiolipin positivity. It should be noted that the patients with only antiphosphatidylinositol positive antibody have a story of nervous system pathology. The meaning of these results is at present under discussion.

show abstract

Do antibodies to β2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome?

Cited by 39 publications

References 33 publications

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment

Antiphospholipid Antibodies in Patients with Cancer

Antiphosphatidylinositol Antibody in Deep Venous Thrombosis Patients

Contact Info

Product

Resources

About